Savara announces encore presentation of results from the phase 3 impala-2 trial of molgramostim inhalation solution (molgramostim) in patients with autoimmune pulmonary alveolar proteinosis (apap) at the british thoracic society winter meeting 2024

Langhorne, pa.--(business wire)--savara inc. (nasdaq: svra) (the company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that an encore presentation of results from the pivotal, phase 3 impala-2 trial will be presented at the british thoracic society (bts) winter meeting, taking place november 27-29, 2024, in london, england. bts platform presentation details title: “inhaled molgramostim improves pulmonary gas exchange and respiratory health-re.
SVRA Ratings Summary
SVRA Quant Ranking